DSDiego de Castro dos Santos

Diego de Castro dos Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Diego de Castro dos Santos has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism

    by André Luiz Santos Pessoa, Thiago Gonçalves Guimarães, Diego de Castro dos Santos, Renata Montes Garcia Barbosa, Ellen Mourao Soares Lopes, Claudio M. de Gusmao, Pedro Lucas Grangeiro Sá Barreto Lima, Matheus Augusto Araújo Castro, Fernando Kok, Paulo Ribeiro Nobrega

    Background: Biallelic variants in DNAJC6 cause PARK‐ DNAJC6 (historically referred to as PARK19), a rare autosomal recessive juvenile‐onset dystonia‐parkinsonism syndrome. Neurodevelopmental delay or regression, epilepsy, movement disorders, and psychiatric symptoms are also present. Progression is fast with frequent bulbar, gastrointestinal involvement and early loss of ambulation. Cases: We report two siblings (17 and 14 years) harboring a novel homozygous nonsense variant in DNAJC6 , p.Cys325*, not previously described in the medical literature and absent from population databases. The variant is predicted to truncate the protein, supporting a loss‐of‐function mechanism consistent with the gene's disease biology. Both patients exhibited developmental regression, parkinsonism with dystonia, cognitive decline, dysphagia, and marked sialorrhea, with severe, accelerated functional deterioration. Levodopa produced only mild benefit; in the older sibling, dose escalation provoked an adverse reaction with sustained upgaze/ophthalmoparesis, opisthotonus, and hypertension. Literature review: We found 23 previously reported DNAJC6 patients, most with early‐onset parkinsonism with variable levodopa responsiveness, frequent developmental and psychiatric comorbidity, and prominent bulbar features. Conclusions: The novel DNAJC6 p.Cys325* variant is associated with severe, early‐onset parkinsonism and developmental regression. DNAJC6 should be considered in children and adolescents presenting with parkinsonism plus neurodevelopmental decline, particularly when levodopa benefit is modest, and dose‐related adverse motor crises occur.

  • The Huntington's Disease Gene Discovery

    by Gustavo L. Franklin, Hélio A.G. Teive, Fernando Spina Tensini, Carlos Henrique Ferreira Camargo, Nayra de Souza Carvalho de Lima, Diego de Castro de dos Santos, Alex T. Meira, Sarah J. Tabrizi

    The gene for Huntington's disease (HD) was discovered in 1993, after an international collaborative initiative that led researchers to remote regions of South America. It was the most remarkable milestone, since George Huntington's initial description. Through the phenomenological discussions led by Jean‐Martin Charcot and Willian Osler, and finally Americo Negrette's reports, which served as the inspiration for the Venezuela Project led by Nancy Wexler, the journey toward discovering the Huntington's disease (HD) gene was marked by substantial efforts. This monumental achievement involved the analysis of more than 18,000 blood samples and gathered dozens of researchers in an integrated effort, enabling the mapping of the gene on chromosome 4 in 1983 and leading, a decade later, to the precise localization and identification of the HTT gene. The discovery of the HD mutation represented a pivotal moment in the field of genetics and neurology, significantly enhancing our understanding of the disease and creating opportunities for future treatments. The progress made and the knowledge gained during this journey catalyzed the development of many innovative molecular techniques that have advanced research in other medical conditions. In this article, the authors celebrate three decades of this memorable event, revisiting the historical aspects, providing insights into the techniques developed, and delving into the paths that ultimately led to the discovery of the HD gene. © 2024 International Parkinson and Movement Disorder Society.


  • Open Access

    Subacute Partially Reversible Leukoencephalopathy Expands the Aicardi–Goutières Syndrome Phenotype

    by Isabella Peixoto de Barcelos, Clarissa Bueno, Luís Filipe S. Godoy, André Pessoa, Larissa A. Costa, Fernanda C. Monti, Katiane Souza-Cabral, Clarice Listik, Diego Castro, Bruno Della-Ripa, et al.

    Objective: To report a series of atypical presentations of Aicardi–Goutières syndrome. Methods: Clinical, neuroimaging, and genetic data. Results: We report a series of six unrelated patients (five males) with a subacute loss of developmental milestones, pyramidal signs, and regression of communication abilities, with onset at ages ranging from 7 to 20 months, reaching a nadir after 4 to 24 weeks. A remarkable improvement of lost abilities occurred in the follow-up, and they remained with residual spasticity and dysarthria but preserved cognitive function. Immunization or febrile illness occurred before disease onset in all patients. CSF was normal in two patients, and in four, borderline or mild lymphocytosis was present. A brain CT scan disclosed a subtle basal ganglia calcification in one of six patients. Brain MRI showed asymmetric signal abnormalities of white matter with centrum semi-ovale involvement in five patients and a diffuse white matter abnormality with contrast enhancement in one. Four patients were diagnosed and treated for acute demyelinating encephalomyelitis (ADEM). Brain imaging was markedly improved with one year or more of follow-up (average of 7 years), but patients remained with residual spasticity and dysarthria without cognitive impairment. Demyelination relapse occurred in a single patient four years after the first event. Whole-exome sequencing (WES) was performed in all patients: four of them disclosed biallelic pathogenic variants in RNASEH2B (three homozygous p.Ala177Thr and one compound heterozygous p.Ala177Thr/p.Gln58*) and in two of them the same homozygous deleterious variants in RNASEH2A (p.Ala249Val). Conclusions: This report expands the phenotype of AGS to include subacute developmental regression with partial clinical and neuroimaging improvement. Those clinical features might be misdiagnosed as ADEM.


  • Open Access

    PUS3 mutations are associated with intellectual disability, leukoencephalopathy, and nephropathy

    by Anderson Rodrigues Brandão de Paiva, David S. Lynch, Uirá Souto Melo, Leandro Tavares Lucato, Fernando Freua, Bruno Della Ripa de Assis, Isabella Barcelos, Clarice Listik, Diego de Castro dos Santos, Lúcia Inês Macedo-Souza, et al.


  • Association of Optic Pathways and Brain Structure With Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia

    by Diego de Castro dos Santos, Egberto Reis Barbosa, Rubens Gisbert Cury

    To the Editor We read with interest the article by Gratwicke et al1 that described deep brain stimulation of the nucleus basalis of Meynert (NBM DBS) and the potential symptomatic effects in patients with Parkinson disease dementia. No consistent improvements were observed in the primary cognitive outcomes. However, the authors found evidence of improvements in neuropsychiatric symptoms, probably driven by a reduction in complex visual hallucinations. Although modest, these findings encourage further DBS research in this subgroup of patients.